Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
RA Capital Management and affiliates reported a significant stake in Contineum Therapeutics, Inc. through a Schedule 13G/A filing. As of December 31, 2025, RA Capital Healthcare Fund, L.P. directly holds 2,179,711 shares of Class A common stock, representing 7.2% of the class.
RA Capital Management, L.P. is investment adviser to the fund and has delegated authority to vote and dispose of these shares. Managers Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners through their control of the adviser. The reporting persons state the securities were not acquired to change or influence control of Contineum.
Janus Henderson Group plc reported a significant ownership stake in Contineum Therapeutics, Inc. Class A common stock. Through its investment adviser subsidiaries managing various client accounts, it may be deemed to beneficially own 2,448,979 shares, representing 7.9% of the class.
The firm reports shared voting and dispositive power over all 2,448,979 shares and no sole voting or dispositive power. The underlying managed portfolios receive all dividends and sale proceeds, including Janus Henderson Biotech Innovation Master Fund Ltd., which alone has rights over more than five percent of the class.
The securities are stated as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Contineum Therapeutics.
Balyasny Asset Management and affiliates report a passive ownership stake in Contineum Therapeutics, Inc. Class A common stock. Through Atlas Diversified Master Fund, Ltd., they beneficially own 2,312,800 shares, representing 7.60% of the class, based on 30,446,111 shares outstanding as of December 12, 2025.
The reporting group includes Balyasny Asset Management L.P., GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Contineum.
Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and related share sale. On February 11, 2026, he exercised 400 stock options at an exercise price of $1.26 per share, receiving 400 shares of Class A common stock.
That same day, he sold 400 Class A common shares at $16.00 per share in an open-market transaction. After these trades, he directly owned 14,954 Class A shares and 128,017 stock options. The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on September 23, 2025, and that the stock options are fully vested and exercisable.
Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. exercised stock options and sold a small block of shares. On February 11, 2026, he exercised options for 400 shares of Class A common stock at $1.01 per share and then sold 400 shares at $16 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he directly owned 156,052 shares of Class A common stock and held 75,530 stock options, with an additional 6,842 shares held indirectly by his spouse.
CTNM insider Daniel Lorrain filed a notice to sell 16,050 shares of common stock. The shares are expected to be sold on 02/11/2026 through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $252,787.50 and 23,099,173 shares outstanding.
The 16,050 shares were acquired the same day via an exercise of stock options paid in cash. The filing also lists prior Rule 10b5‑1 sales of CTNM common stock by Lorrain over the past three months, each involving 4,170 shares with disclosed gross proceeds.
A shareholder of CTNM has filed a notice of intent to sell 7,500 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $118,125.00 and an approximate sale date of 02/11/2026. These shares are shown as being acquired on the same date by exercise of stock options for cash. The filing also notes total common shares outstanding of 23,099,173 for context.
Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. reported planned stock sales under a prearranged Rule 10b5-1 trading plan. On February 3, 2026, the insider sold 3,000 shares of Class A common stock at a weighted average price of $14.8229 and 1,170 shares at a weighted average price of $15.2451. The prices in each trade reflect multiple executions within disclosed ranges. After these transactions, the officer directly held 156,052 shares of Class A common stock and had an additional 6,842 shares reported as indirectly owned by a spouse.
An insider of CTNM has filed a notice of intent to sell shares. The filing covers 4,170 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $59,964.60 and 23,099,173 shares outstanding.
The shares were originally acquired as 4,170 restricted stock units from the issuer on May 9, 2017. The same account has sold 4,170 shares on December 23, 2025 for $51,009.11 and another 4,170 shares on January 5, 2026 for $43,543.06 under a Rule 10b5‑1 trading plan for Daniel Lorrain.
Contineum Therapeutics reported that its General Counsel and Corporate Secretary, John Stephen Healy, received a grant of stock options on January 30, 2026. The award covers 206,411 shares of Class A common stock at an exercise price of $14.26 per share.
The options were granted under the company’s 2024 Equity Incentive Plan and vest in equal monthly installments over 48 months, conditioned on Healy’s continued service with the company. Following this grant, he beneficially owns 206,411 stock options, held directly.